GRI Bio, Inc.
$2.51
▲
0.63%
2026-04-21 07:10:02
www.gribio.com
NCM: GRI
Explore GRI Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.68 M
Current Price
$2.51
52W High / Low
$80.36 / $2.1
Stock P/E
—
Book Value
$12.07
Dividend Yield
—
ROCE
-198.85%
ROE
-2.38%
Face Value
—
EPS
$-121.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
3
Beta
-1.24
Debt / Equity
1.18
Current Ratio
3.25
Quick Ratio
3.25
Forward P/E
-0.31
Price / Sales
—
Enterprise Value
$-4.62 M
EV / EBITDA
0.39
EV / Revenue
—
Rating
None
Target Price
$160
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ACADIA Pharmaceuticals Inc. | $22.09 | 9.63 | $3.77 B | — | 8.14% | 39.89% | $28.35 / $14.08 | $7.21 |
| 2. | Halozyme Therapeutics, Inc. | $68.8 | 26.89 | $8.18 B | — | 34.18% | 1.54% | $82.22 / $47.5 | $0.41 |
| 3. | TScan Therapeutics, Inc. | $1.43 | — | $67.71 M | — | -64.64% | -71.28% | $2.57 / $0.88 | $2.16 |
| 4. | Gossamer Bio, Inc. | $0.42 | — | $98.57 M | — | -150.03% | 365.33% | $3.87 / $0.32 | $-0.53 |
| 5. | Dermata Therapeutics, Inc. | $1.34 | — | $5.47 M | — | -124.91% | -1.94% | $9.9 / $1.1 | $2.34 |
| 6. | Milestone Pharmaceuticals Inc. | $2.04 | — | $247.1 M | — | -62.4% | -2.3% | $3.06 / $0.77 | $0.34 |
| 7. | Elicio Therapeutics, Inc. | $12.2 | — | $224.43 M | — | -210.11% | 817.92% | $14.93 / $4.7 | $0.09 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.66 M | -3.37 M | -2.9 M | -3.05 M | -1.95 M | — |
| Net Profit | -2.66 M | -3.36 M | -2.89 M | -3.05 M | -1.95 M | — |
| EPS in Rs | -1.84 | -2.32 | -2 | -2.11 | -1.35 | -319.76 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -11.98 M | -8.23 M | -11.39 M | -2.24 M |
| Net Profit | -11.96 M | -8.21 M | -13.04 M | -3.22 M |
| EPS in Rs | -8.27 | -5.68 | -9.02 | -2.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.67 M | 5.74 M | 2.96 M | 0.38 M |
| Total Liabilities | 2.66 M | 1.71 M | 2.7 M | 2.01 M |
| Equity | 6.01 M | 4.03 M | 0.26 M | -1.62 M |
| Current Assets | 8.59 M | 5.62 M | 2.93 M | 0.31 M |
| Current Liabilities | 2.64 M | 1.64 M | 2.7 M | 1.99 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.19 M | -8.61 M | -8.99 M | -1.08 M |
| Investing CF | -0 M | 0 M | -0.01 M | -0 M |
| Financing CF | 13.39 M | 11.83 M | 10.8 M | 1.01 M |
| Free CF | -10.19 M | -8.61 M | -9 M | -1.09 M |
| Capex | -0 M | — | -0.01 M | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 37.05% | -305.25% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-01-26 | 1:0.0357143 |
| 2025-02-24 | 1:0.0588235 |
| 2024-06-18 | 1:0.0769231 |
| 2024-01-30 | 1:0.142857 |
| 2023-04-24 | 1:0.0333333 |